Uses of Platosin

Platosin drug is prepared in the form of a solution for injection of 1mg/1ml, the main active ingredient is Cisplatin, the effectiveness of the drug's cancer treatment is due to the pharmacology of the main ingredient. Cisplatin is a pharmacodynamic anti-cancer drug. The drug is a platinum compound, the active new cis isomer form. Cisplatin creates an internal cross-link, in between two DNA strands, which changes the structure, inhibits DNA synthesis. In addition, the drug also inhibits the synthesis of RNA and proteins. This effect is not stage-specific in the cell cycle. Cisplatin is concentrated in the liver, small intestine, and testes. The drug enters the cerebrospinal fluid less because it does not cross the blood-brain barrier. The concentration of the drug in the cerebrospinal fluid is low, the amount of drug found in brain tumors is high. Animal studies have shown the drug to enter the uterus and ovaries. After intravenous infusion, the drug is broken down in two stages. The first phase is rapid, with a half-life ranging from 25 minutes to 49 minutes. The post-elimination phase is longer with a half-life ranging from 2 days to 4 days. On average about 90% of the drug is bound to plasma proteins, but possibly more. Platosin is mainly excreted in the urine through a filter from the kidneys. Approximately 15-25% of the drug is eliminated rapidly as unchanged drug in the first 2 to 4 hours and about 20-75% is eliminated in the first 24 hours. The remainder of the drug is retained in organ tissue or bound to plasma proteins.

2.1. Indications Platosin is effective in the following cancers:
Small cell bronchial cancer and non-small cell cancer. Testicular and prostate cancer. Ovarian cancer, uterine lining, pelvis. Head, face and neck cancer, intercellular carcinoma, lymphoma. 2.2. Contraindications Do not use Platosin in the following contraindications:
Patients who are allergic to cisplatin, the excipients contained in the drug Platosin. Patients with severe kidney failure, bone marrow failure. Pregnant women, lactating women should not take Platosin. Patients who are suffering from chickenpox, shingles, gout, have urate stones, who are suffering from infectious diseases, peripheral neuropathy.

Platosin is intended for intravenous infusion, which must be completed within 24 hours, and the remainder should be discarded when not used up.
Dosage of drug solution each time according to the formula 50 - 120 mg/m2 body skin for every 4 weeks. Or use a daily dose of 15-20 mg/m2 of body skin for 5 consecutive days. Use the above dose again after 3 weeks - 4 weeks.
Some notes in the process of using the drug:
The drug can be mixed into 1 liter of 0.9% NaCl solution. The patient should be infused with enough water before and within 24 hours after infusion to ensure urine output and minimize nephrotoxic effects. Water infusion before drug administration: 2 liters of 5% glucose solution in 1/2 or 1⁄3 of 0.9% NaCl solution can be infused intravenously over 2 to 4 hours. Fluid infusion after drug treatment: It is very important to maintain enough water and urine for 24 hours after drug infusion.

During the use of Platosin, patients may experience the following undesirable side effects:
Renal failure, microscopic hematuria, increased blood urea, urine urea, increased uric acid. Bone marrow toxicity may occur with leukopenia and thrombocytopenia, and subsequently anemia, but resolves with discontinuation of the drug. Digestive disorders: vomiting, nausea, loss of appetite, change in taste, inflammation of the small intestine. Tinnitus, hearing loss. Signs of allergy, anaphylactoid reactions, are facial edema, tachycardia, wheezing, rash, hypotension, dysesthesia. Liver failure, retinal toxicity such as blurred vision, altered color perception, visual disturbances, optic neuritis, cardiotoxicity, electrolyte disturbances. Peripheral neuropathy: paresthesia, loss of reflexes, loss of self-sensory perception, sensation of tremors...

The drug is used as prescribed by the oncologist, the patient needs to adhere to the treatment and note the following issues:
The patient being treated should notify the doctor about the drugs being used, including including prescription and non-prescription drugs, dietary supplements. Because Platosin drug interacts with the following drugs: Cephalosporins, myelosuppressive drugs, radiotherapy drugs. drugs to treat gout, aminoglycoside drugs... Drugs are retained in the kidneys, so the kidneys are susceptible to toxicity due to drug accumulation. Patients need to be infused with enough other infusion solutions before, while taking the drug, to ensure enough urine, to avoid drug stagnation. Drugs that are toxic to liver function: Studies have shown high levels of the drug in the liver. High AST and alkaline phosphatase. Platosin should be used with caution in patients with pre-existing liver dysfunction. It is recommended to do basic audiograms and periodically monitor the patient to detect any damage to the patient's hearing. If the skin and mucous membranes suddenly become contaminated with Platosin, it should be washed immediately with clean water and soap thoroughly. People who need to be safe to drive vehicles and operate machinery should use caution when using Platosin. Above is information about the use of Platosin. The drug is prescribed for cancer patients, patients should not use it on their own. When taking the drug, the patient should follow the dosage instructions, the necessary notes to avoid unwanted effects when using Platosin. If you still have questions about cancer treatment drug Platosin, please contact a specialist for help.